| Next-generation GLP-1 therapy: an introduction to liraglutide. | |
| | |
MedLine Citation:
|
PMID: 21904107 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Liraglutide, a once-daily human glucagon-like peptide-1 (GLP-1) analog, was approved by the US Food and Drug Administration in 2010 for the treatment of type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 enhances insulin secretion and inhibits glucagon in a glucose-dependent manner. The efficacy and safety of liraglutide were evaluated in 6 phase 3 trials in > 4000 patients in the Liraglutide Effect and Action in Diabetes (LEAD) program, in another trial in comparison with sitagliptin, and in another trial where basal insulin was added to liraglutide + metformin. At liraglutide doses of 1.2 mg or 1.8 mg once daily, significant mean reductions in glycated hemoglobin (HbA1c) (1%-1.6%) and fasting plasma glucose (15-43 mg/dL), as well as sustained weight loss (2-3 kg) and a low rate of hypoglycemia occurred. Mild and transient nausea, reported in 6% to 41% of patients, was the most frequent adverse event reported. Incretin-based therapies such as liraglutide provide an important expansion of options for the treatment of T2DM. |
| | |
Authors:
|
Thomas Repas |
Related Documents
:
|
17444967 - The collaborative study of obesity and diabetes in adults (coda) project: meta-analysis... 18282177 - Dousing our inflammatory environment(s): is personal carbon trading an option for reduc... 20827427 - Carotid intima-media thickness in childhood and adolescent obesity relations to abdomin... 3326847 - A pharmacotherapeutic approach to the regulation of hyperinsulinemia and obesity. 1967767 - Comparison of insulin analogue b9aspb27glu and soluble human insulin in insulin-treated... 8075467 - Success rates in producing sympathetic blockade by paratracheal injection. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Postgraduate medicine Volume: 123 ISSN: 1941-9260 ISO Abbreviation: Postgrad Med Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-09-09 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0401147 Medline TA: Postgrad Med Country: United States |
Other Details:
|
Languages: eng Pagination: 239-47 Citation Subset: AIM; IM |
Affiliation:
|
Regional Medical Clinic, Aspen Centre-Endocrinology, Rapid City, SD. Trepas@rcrh.org. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Next Document: Induction of steroid sulfatase expression by tumor necrosis factor-a through PI 3-kinase/Akt signali...